Expertise in
22
conditions

Dr. Neal D. Shore

Urology
Atlantic Urology Clinics - Myrtle Beach
823 82nd Pkwy, 
Myrtle Beach, SC 
Accepting New Patients
Offers Telehealth
Expertise in
22
conditions
Atlantic Urology Clinics - Myrtle Beach
823 82nd Pkwy, 
Myrtle Beach, SC 

Overview

Neal Shore is a Urologist practicing medicine in Myrtle Beach, South Carolina.

Dr. Shore is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Familial Prostate Cancer, Bladder Cancer, Orchiectomy, and Prostatectomy.

He is actively involved in clinical research, co-authoring 509 peer reviewed articles and participating in 33 clinical trials. Dr. Shore is currently accepting new patients.

Specialties

Urology

Licenses

Urology in SC

Hospital Affiliations

Conway Medical Center
Tidelands Waccamaw Community Hospital
Tidelands Georgetown Memorial Hospital
Grand Strand Regional Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Absolute Total Care South Carolina
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Clover Health
  • INSURANCE PLAN
  • MEDICARE MAPD
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

Atlantic Urology Clinics - Myrtle Beach
823 82nd Pkwy, Myrtle Beach, SC 29572

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

33 Clinical Trials

PSMAfore: A Phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of Androgen Receptor-Directed Therapy in the Treatment of Taxane Naïve Men With Progressive Metastatic Castrate Resistant Prostate Cancer
PSMAfore: A Phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of Androgen Receptor-Directed Therapy in the Treatment of Taxane Naïve Men With Progressive Metastatic Castrate Resistant Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 26, 2026
Intervention Type: Drug
Study Drug: ARDT
Study Phase: Phase 3
A Prospective, Multicenter, Double Blind, Randomized, Clinical Study to Evaluate the Safety and Efficacy of the Optilume™ BPH Catheter System in Men With Symptomatic BPH
A Prospective, Multicenter, Double Blind, Randomized, Clinical Study to Evaluate the Safety and Efficacy of the Optilume™ BPH Catheter System in Men With Symptomatic BPH
Enrollment Status: Active_not_recruiting
Publish Date: July 30, 2026
Intervention Type: Device
Study Phase: Not Applicable
A Phase 3 Study of Cretostimogene Grenadenorepvec in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus-Calmette-Guerin (BCG)
A Phase 3 Study of Cretostimogene Grenadenorepvec in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus-Calmette-Guerin (BCG)
Enrollment Status: Active_not_recruiting
Publish Date: July 10, 2026
Intervention Type: Other, Biological
Study Drugs: CG0070, N-Dodecyl-B-D-Maltoside
Study Phase: Phase 3
An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
Enrollment Status: Active_not_recruiting
Publish Date: June 08, 2026
Intervention Type: Drug
Study Drugs: 177Lu-PSMA-617, Androgen Receptor Directed Therapy, Androgen Deprivation Therapy
Study Phase: Phase 3
CISTO: Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer
CISTO: Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer
Enrollment Status: Active_not_recruiting
Publish Date: May 12, 2026
A Randomized Controlled Trial of ProstAtak® as Adjuvant to Up-front Radiation Therapy For Localized Prostate Cancer
A Randomized Controlled Trial of ProstAtak® as Adjuvant to Up-front Radiation Therapy For Localized Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 30, 2025
Intervention Type: Biological
Study Drugs: Aglatimagene besadenovec, Valacyclovir
Study Phase: Phase 3
A Phase 1/2a Pilot Study of Intravesical TSD-001 for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer
A Phase 1/2a Pilot Study of Intravesical TSD-001 for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer
Enrollment Status: Completed
Publish Date: June 27, 2025
Intervention Type: Drug
Study Drug: Paclitaxel
Study Phase: Phase 1/Phase 2
Use of a Multiplexed Molecular Biomarker Test Cxbladder, in Real World Decision Making to Provide Clinical Utility Using a Randomized Design (STRATA Study)
Use of a Multiplexed Molecular Biomarker Test Cxbladder, in Real World Decision Making to Provide Clinical Utility Using a Randomized Design (STRATA Study)
Enrollment Status: Completed
Publish Date: May 31, 2025
Intervention Type: Diagnostic test
Study Phase: Not Applicable
A Multicenter, Open-Label, Parallel, Phase 1b/2a Study of PLX2853 in Combination With Abiraterone Acetate and Prednisone and Phase 1b/2a Study of PLX2853 in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
A Multicenter, Open-Label, Parallel, Phase 1b/2a Study of PLX2853 in Combination With Abiraterone Acetate and Prednisone and Phase 1b/2a Study of PLX2853 in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Enrollment Status: Terminated
Publish Date: April 08, 2025
Intervention Type: Drug
Study Drugs: PLX2853, Olaparib, Abiraterone acetate, Prednisone
Study Phase: Phase 1/Phase 2
VISION: An International, Prospective, Open Label, Multicenter, Randomized Phase 3 Study of 177Lu-PSMA-617 in the Treatment of Patients With Progressive PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)
VISION: An International, Prospective, Open Label, Multicenter, Randomized Phase 3 Study of 177Lu-PSMA-617 in the Treatment of Patients With Progressive PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Enrollment Status: Completed
Publish Date: January 13, 2025
Intervention Type: Drug, Other
Study Drug: 177Lu-PSMA-617
Study Phase: Phase 3
View 9 Less Clinical Trials

509 Total Publications

Commentary on "matching-adjusted indirect comparison of enzalutamide versus darolutamide doublet in mHSPC".
Commentary on "matching-adjusted indirect comparison of enzalutamide versus darolutamide doublet in mHSPC".
Journal: Future oncology (London, England)
Published: August 08, 2026
Similar Doctors
Expertise in
45
conditions
Expertise in
45
conditions
Referral may be required

Atlantic Urology Clinics LLC

3600 Sea Mountain Hwy Ste B, 
Little River, SC 
 (11.9 miles away)
843-236-4949
Languages Spoken:
English
See accepted insurances

Glenn Gangi is a Urologist practicing medicine in Little River, South Carolina. Dr. Gangi is highly rated in 45 conditions, according to our data. His clinical expertise encompasses UPJ Obstruction, Perirenal Abscess, Boils, Ureteroscopy, and Reconstructive Urology Surgery.

Expertise in
25
conditions
Expertise in
25
conditions
Referral may be required

Atlantic Urology Clinics - Myrtle Beach

823 82nd Pkwy, 
Myrtle Beach, SC 
 (0.1 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Brian Roberts is a Urologist practicing medicine in Myrtle Beach, South Carolina. Dr. Roberts is highly rated in 25 conditions, according to our data. His clinical expertise encompasses Familial Prostate Cancer, Prostate Cancer, Kidney Stones, Ureteroscopy, and Bladder Reconstruction. Dr. Roberts is currently accepting new patients.

Expertise in
26
conditions
Expertise in
26
conditions
Referral may be required
Before you request

AUC Urologists LLC

135 Professional Park Dr, 
Conway, SC 
 (9.8 miles away)
843-347-8765
Languages Spoken:
English
See accepted insurances
Accepting New Patients

James Fogarty is a Urologist practicing medicine in Conway, South Carolina. Dr. Fogarty is highly rated in 26 conditions, according to our data. His clinical expertise encompasses UPJ Obstruction, Obstructive Uropathy, Stress Urinary Incontinence, Urinary Incontinence, and Ureteroscopy. Dr. Fogarty is currently accepting new patients.

Frequently Asked Questions about Dr. Neal D. Shore

Is Dr. Neal D. Shore a top-rated expert for Prostate Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Neal D. Shore is classified as an Elite expert for Prostate Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Neal D. Shore specialize in?

While Dr. Neal D. Shore is a Urology, they have specific expertise in Prostate Cancer, Familial Prostate Cancer, and Bladder Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Urology.

Does Dr. Neal D. Shore participate in research or clinical trials?

Yes. Dr. Neal D. Shore has published 509 articles and abstracts on conditions like Prostate Cancer. You can view a list of Dr. Neal D. Shore's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Neal D. Shore accept my insurance?

Dr. Neal D. Shore accepts most major insurance plans, including Absolute Total Care South Carolina and Aetna. We recommend calling the office directly to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Shore's expertise for a condition
ConditionClose
View All 13 Advanced Conditions
View All 25 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile